MCID: OPN001
MIFTS: 48

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Rare diseases, Fetal diseases

Aliases & Classifications for Open-Angle Glaucoma

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 14
Glaucoma, Open-Angle 42 69
Open Angle Glaucoma 12
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 52
Glaucoma Simplex 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1067
MeSH 42 D005902
NCIt 47 C34641
UMLS 69 C0017612

Summaries for Open-Angle Glaucoma

Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1a, primary open angle and residual stage of open angle glaucoma. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Elastic fibre formation. The drugs Travoprost and Apraclonidine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial.

Related Diseases for Open-Angle Glaucoma

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1a, Primary Open Angle Glaucoma 3a, Primary Open Angle, Congenital, Juvenile, or Adult Onset
Glaucoma 1, Open Angle, P Glaucoma 1, Open Angle, I
Glaucoma 1, Open Angle, 1o Glaucoma, Primary Open Angle, Juvenile-Onset, 2

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 glaucoma 1a, primary open angle 34.2 CYP1B1 MYOC OPTN
2 residual stage of open angle glaucoma 12.2
3 glaucoma 1, open angle, e 12.2
4 glaucoma 1, open angle, p 11.9
5 glaucoma 1, open angle, f 11.9
6 glaucoma 1, open angle, 1o 11.8
7 glaucoma 1, open angle, g 11.8
8 exfoliation syndrome 11.5
9 ocular hypertension 10.9
10 intracranial berry aneurysm 10.8 CYP1B1 OPTN
11 conjunctival folliculosis 10.8 CYP1B1 OPTN
12 opisthorchiasis 10.7 CYP1B1 MYOC OPTN
13 mitral valve prolapse, myxomatous 3 10.7 ASB10 OPTN
14 acute poststreptococcal glomerulonephritis 10.7 CYP1B1 MYOC OPTN
15 familial male-limited precocious puberty 10.7 CYP1B1 MYOC
16 glaucoma 3a, primary open angle, congenital, juvenile, or adult onset 10.7 CYP1B1 MYOC OPTN
17 myopathy of extraocular muscle 10.7 MYOC OPTN TMCO1
18 retinitis 10.6
19 mixed gonadal dysgenesis 10.6 OPTN TGFB2
20 taeniasis 10.6 CYP1B1 MYOC OPTN WDR36
21 primary angle-closure glaucoma 10.5
22 asbestos intoxication 10.5 GSTM1 GSTT1
23 secondary corneal edema 10.5 CYP1B1 MMP1 MYOC OPTN
24 cataract 10.4
25 holoprosencephaly 2 10.4 SIX1 SIX6
26 myopia 10.3
27 congenital ichthyosiform erythroderma 10.3 OPTN TGFB2
28 nail disorder, nonsyndromic congenital, 1 10.3 CYP1B1 MMP1 MYOC OPTN WDR36
29 orbital lymphoma 10.3 GSTM1 GSTT1
30 neuropathy 10.3
31 endotheliitis 10.3
32 choroiditis 10.3
33 glaucoma, normal tension 10.2
34 primary congenital glaucoma 10.2
35 ocular hypotension 10.2
36 ischemic optic neuropathy 10.2
37 amenorrhea 10.1 OPTN SIX1
38 acute pancreatitis 10.1 CDKN2B-AS1 GSTM1 GSTT1
39 dementia 10.1
40 retinal vein occlusion 10.1
41 optic atrophy plus syndrome 10.1 CDKN2B-AS1 LOXL1 MYOC OPTN TBK1 WDR36
42 senile cataract 10.0
43 allergic contact dermatitis of eyelid 10.0 ELN MYOC OPTN
44 olecranon bursitis 10.0 ELN LOXL1 OPTN
45 hemoglobin lepore-beta-thalassemia syndrome 10.0 ELN MMP1
46 steroid-induced glaucoma 10.0
47 kearns-sayre syndrome 10.0
48 pulmonary hypertension 10.0
49 thyroiditis 10.0
50 nevus of ota 10.0

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma

Symptoms & Phenotypes for Open-Angle Glaucoma

Drugs & Therapeutics for Open-Angle Glaucoma

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1 157283-68-6 5282226
2
Apraclonidine Approved Phase 4 66711-21-5 2216
3
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
4
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130209-82-4 5282380 5311221
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
6
Dorzolamide Approved Phase 4,Phase 3,Phase 2 120279-96-1 3154 5284549
7
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 26839-75-8 33624 5478
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Brinzolamide Approved Phase 4,Phase 3,Phase 2 138890-62-7 68844
10
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155206-00-1 5311027
11
Sorbitol Approved Phase 4 50-70-4 5780
12
Pilocarpine Approved Phase 4 54-71-7, 92-13-7 5910
13
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
14
Bevacizumab Approved, Investigational Phase 4 216974-75-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
17
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2 110-16-7 444266
20 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
23 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1 70359-46-5
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
29 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Ketorolac Tromethamine Phase 4
37 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
38 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1
39 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
42 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Alkylating Agents Phase 4,Phase 3,Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
45 Lubricant Eye Drops Phase 4,Phase 3,Phase 2
46 Cloprostenol Phase 4,Phase 3
47 Contraceptive Agents Phase 4,Phase 3
48 Luteolytic Agents Phase 4,Phase 3
49 Cathartics Phase 4
50 Gastrointestinal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 667)

id Name Status NCT ID Phase Drugs
1 Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty Unknown status NCT01444105 Phase 4
2 Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery Unknown status NCT01455467 Phase 4
3 A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients. Unknown status NCT00326066 Phase 4
4 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Unknown status NCT01443988 Phase 4 Travoprost
5 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Unknown status NCT01444040 Phase 4 Travoprost
6 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
7 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
8 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252888 Phase 4
9 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Unknown status NCT01252862 Phase 4
10 Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects Unknown status NCT01252849 Phase 4
11 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
12 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
13 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
14 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
15 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
16 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
17 Choroidal Thickness in Glaucoma Patients and Healthy Controls Unknown status NCT01293474 Phase 4
18 Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3 Unknown status NCT01299233 Phase 4
19 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
20 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
21 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
22 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects Completed NCT00326040 Phase 4
23 A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
24 24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
25 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
26 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
27 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
28 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
29 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
30 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
31 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
32 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
33 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
34 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
35 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
36 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma Completed NCT00444080 Phase 4
37 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
38 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
39 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons Completed NCT01853085 Phase 4 Bimatoprost Ophthalmic Solution
40 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
41 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
42 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
43 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
44 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
45 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
46 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
47 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
48 Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. Completed NCT00801437 Phase 4 Xalacom
49 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
50 Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® Completed NCT00486252 Phase 4

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: glaucoma, open-angle

Genetic Tests for Open-Angle Glaucoma

Anatomical Context for Open-Angle Glaucoma

MalaCards organs/tissues related to Open-Angle Glaucoma:

39
Eye, Testes, Endothelial, Brain, Cortex, Skin, Bone

Publications for Open-Angle Glaucoma

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 1282)
id Title Authors Year
1
New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. ( 28073927 )
2017
2
Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway. ( 28952395 )
2017
3
Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue. ( 28053501 )
2017
4
Variations in optic nerve head morphology by intraocular pressure in open-angle glaucoma. ( 28875349 )
2017
5
Presumed Solar Retinopathy in Child With Juvenile Open-Angle Glaucoma. ( 28820920 )
2017
6
Assessment of peripapillary choroidal thickness in primary open-angle glaucoma patients with choroidal vascular prominence. ( 28929241 )
2017
7
Use of 5-Fluorouracil-Soaked Bioamniotic Membranes in Trabeculectomy for Primary Open-Angle Glaucoma: A Retrospective Analysis. ( 28845303 )
2017
8
Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. ( 28850575 )
2017
9
Effect of phacoemulsification on intraocular pressure in patients with primary open angle glaucoma and pseudoexfoliation glaucoma. ( 28944195 )
2017
10
A Histologic Categorization of Aqueous Outflow Routes in Familial Open-Angle Glaucoma and Associations With Mutations in the MYOC Gene in Japanese Patients. ( 28564705 )
2017
11
Association of intraocular pressure related factors and retinal vessel diameter with optic disc rim area in subjects with and without primary open angle glaucoma. ( 28858414 )
2017
12
Association of WDR36 polymorphisms with primary open angle glaucoma: A systematic review and meta-analysis. ( 28658128 )
2017
13
Comparison of self-measured diurnal intraocular pressure profiles using rebound tonometry between primary angle closure glaucoma and primary open angle glaucoma patients. ( 28333942 )
2017
14
Comparison of the Retinal Microvascular Density Between Open Angle Glaucoma and Nonarteritic Anterior Ischemic Optic Neuropathy. ( 28687846 )
2017
15
The association between skin autofluorescence and mean deviation in patients with open-angle glaucoma. ( 27941048 )
2017
16
Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma. ( 27862086 )
2017
17
Additive effects of genetic variants associated with intraocular pressure in primary open-angle glaucoma. ( 28832686 )
2017
18
Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015). ( 28076854 )
2017
19
Contribution of Mutations in Known Mendelian Glaucoma Genes to Advanced Early-Onset Primary Open-Angle Glaucoma. ( 28282485 )
2017
20
Genetic correlations between intraocular pressure, blood pressure and primary open-angle glaucoma: a multi-cohort analysis. ( 28853718 )
2017
21
Selective Laser Trabeculoplasty vs. Fixed Combinations with Timolol in Practice: A Replacement Study in Primary Open Angle Glaucoma. ( 28845323 )
2017
22
Success rates of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C for primary angle-closure glaucoma and primary open-angle glaucoma in an Asian population. ( 28188405 )
2017
23
Canaloplasty with Stegmann Canal Expander for primary open-angle glaucoma: two-year clinical results. ( 28083899 )
2017
24
Change in Visual Field Progression Following Treatment Escalation in Primary Open-angle Glaucoma. ( 28834827 )
2017
25
Diurnal macular choroidal area fluctuation in normal and primary open angle glaucoma groups. ( 28861348 )
2017
26
Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. ( 28652689 )
2017
27
Long-term efficacy and safety of ExPress implantation for treatment of open angle glaucoma. ( 28944196 )
2017
28
Phenotypic differences between familial versus non-familial Juvenile onset open angle glaucoma patients. ( 28910179 )
2017
29
Validity of code based algorithms to identify primary open angle glaucoma (POAG) in Veterans Affairs (VA) administrative databases. ( 28945495 )
2017
30
Identification of genes associated with primary open-angle glaucoma by bioinformatics approach. ( 28894971 )
2017
31
Health care claims for primary open-angle glaucoma and retinal vein occlusion from an 11-year nationwide dataset. ( 28808282 )
2017
32
Trabecular Meshwork Height in Primary Open-Angle Glaucoma Versus Primary Angle-Closure Glaucoma. ( 28887118 )
2017
33
Genetic Variant Near PLXDC2 Influences the Risk of Primary Open-angle Glaucoma by Increasing Intraocular Pressure in the Japanese Population. ( 28930887 )
2017
34
The role of hypertension in retinal blood flow alterations in open-angle glaucoma patients. ( 28084046 )
2017
35
Pseudophakic Macular Edema in Primary Open-Angle Glaucoma: A Prospective Study Using Spectral-Domain Optical Coherence Tomography. ( 28941649 )
2017
36
Analysis of Cyclin-Dependent Kinase Inhibitor-2B rs1063192 Polymorphism in Saudi Patients with Primary Open-Angle Glaucoma. ( 27541204 )
2016
37
Investigation of the Rho-kinase Gene Polymorphism in Primary Open-angle Glaucoma. ( 24617500 )
2016
38
Elevated urine formaldehyde in elderly patients with primary open angle glaucoma. ( 27158612 )
2016
39
Subconjunctival sustained-release dexamethasone implant as an adjunct to trabeculectomy for primary open angle glaucoma. ( 27146944 )
2016
40
Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up. ( 27174381 )
2016
41
Medical therapy versus trabeculectomy in patients with open-angle glaucoma. ( 27626147 )
2016
42
The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. ( 27162226 )
2016
43
The Effects of Nocturnal Dip and Blood Pressure Variability on Paracentral Scotoma in Early Open-Angle Glaucoma. ( 27128963 )
2016
44
Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: the LUNAR Study. ( 27210275 )
2016
45
Trabeculectomy Versus Ex-Press Glaucoma Filtration Device in Silicomacrophagocytic Open Angle Glaucoma Secondary to Silicone Oil Emulsification. ( 27162449 )
2016
46
Impact of Socioeconomic Status on the Diagnosis of Primary Open-Angle Glaucoma and Primary Angle Closure Glaucoma: A Nationwide Population-Based Study in Taiwan. ( 26905307 )
2016
47
Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans. ( 27217714 )
2016
48
Ocular characteristics associated with the location of focal lamina cribrosa defects in open-angle glaucoma patients. ( 27935604 )
2016
49
Real-Time Ultrasound Elastographic Features of Primary Open Angle Glaucoma. ( 27599308 )
2016
50
Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma. ( 27173373 )
2016

Variations for Open-Angle Glaucoma

Expression for Open-Angle Glaucoma

Search GEO for disease gene expression data for Open-Angle Glaucoma.

Pathways for Open-Angle Glaucoma

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.68 ELN LOXL1 MMP1 OPTC TGFB2
2
Show member pathways
11 ELN LOXL1 TGFB2
3 10.54 GSTM1 GSTT1

GO Terms for Open-Angle Glaucoma

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.35 ELN LOXL1 MMP1 MYOC OPTC
2 extracellular matrix GO:0031012 8.92 LOXL1 MMP1 MYOC TGFB2

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glutathione derivative biosynthetic process GO:1901687 9.26 GSTM1 GSTT1
2 generation of neurons GO:0048699 9.16 SIX1 TGFB2
3 extracellular matrix disassembly GO:0022617 9.13 ELN MMP1 OPTC
4 positive regulation of xenophagy GO:1904417 8.62 OPTN TBK1

Sources for Open-Angle Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....